SpineGuard, based in San Francisco and Paris, is addressing a major unmet need in spine surgery: the safe placement of pedicle screws for both patients and OR personnel. PediGuard®, its core technology, is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches during pedicle screw site preparation.
San Diego, CA January 8, 2013 – Ridge Diagnostics, Inc., a neurodiagnostic company, announced that Lonna J. Williams, CEO, will speak at the 6th Annual OneMedForum San Francisco 2013, to be held at The Sir Francis Drake Hotel on January 8, 2013 at 2:10pm.
Cognoptix, presenting at the 6th Annaul OneMedForum, January 7-9 in San Francisco, is a privately held medical device company creating and developing a simple, innovative non-invasive eye scanning test for the early detection and diagnosis of Alzheimer’s Disease.
As part of our look into the impact of the JOBS Act on emerging growth companies, OneMedForum will feature a panel devoted to the subject of crowdfunding in life sciences and new investment strategies following the implementation of this groundbreaking legislation.
What if there was a way to substantially reduce high blood pressure for patients who have tried everything? Renal denervation is a hot topic, and ReCor Medical offers a unique ultrasound approach to enhance this exciting therapy…
OneMedRadio spoke with Clinova, a British pharmaceutical company focused on developing, manufacturing and marketing consumer healthcare products and medical device, has a rare global presence in multiple emerging markets, while also securing a significant market presence in Europe.
The first start-up by Bob Ward—The Polymer Technology Group (PTG)—earned a 555X return for investors upon its sale in 2008 to DSM, the global life sciences and materials company. Now, Bob Ward’s swinging away at another potential homerun: ExThera Medical, a Berkeley, California-based company, with its scientific origins at the Karolinska Institute in Stockholm, Sweden.
In the US and EU, HF is one of the most frequent diagnoses, and accounts for 7.5 million hospital days per year. Three to five percent of patients die despite hospitalization, half go home unimproved, 25% are readmitted within 30 days, and 30% die in six months.
DBV Technologies, whose shares are traded on segment C of Euronext Paris (Ticker: DBV), believes that its VIASKIN® platform is a game-changer, notably for children and adults who suffer from potentially lethal food allergies.
Acton, Mass.-based Cognoptix (formerly Neuroptix) has developed an entirely novel, early-stage diagnostic for Alzheimer’s disease (AD) to allow treatment before significant neuronal loss and irreversible brain damage occurs.
Copyright © 2024 | WordPress Theme by MH Themes